We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UK Pharma Giant’s China Woes Offer Cautionary Tale for Devicemakers
UK Pharma Giant’s China Woes Offer Cautionary Tale for Devicemakers
August 6, 2013
As senior officials of GlaxoSmithKline face accusations of bribing Chinese government officials, experts on the U.S. Foreign Corrupt Practices Act (FCPA) say the case offers a cautionary tale on how to conduct — or not conduct — business in a foreign market.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor